Biological Therapeutic Modalities for Intervertebral Disc Diseases: An Orthoregeneration Network (ON) Foundation Review
Arthroscopy · 2024-03 · 40 (3) · 1019-1030
DOI: 10.1016/j.arthro.2023.10.032 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Arthroscopy, online erschienen am 31.10.2023. Verfasst von Shuichi Mizuno und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, U.S.A. Hauptthemen laut MEDLINE: Biological Products, Intervertebral Disc, Intervertebral Disc Degeneration, Intervertebral Disc Displacement. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
Orthoregeneration is defined as a solution for orthopaedic conditions that harnesses the benefits of biology to improve healing, reduce pain, improve function, and, optimally, provide an environment for tissue regeneration. Options include drugs, surgical intervention, scaffolds, biologics as a product of cells, and physical and electromagnetic stimuli. The goal of regenerative medicine is to enhance the healing of tissue after musculoskeletal injuries as both isolated treatment and adjunct to surgical management, using novel therapies to improve recovery and outcomes. Various orthopaedic biologics (orthobiologics) have been investigated for the treatment of pathology involving the spine, including lower back pain, with or without numbness and/or dysfunction in the lower extremities, disc herniation, spinal stenosis, and spondylolisthesis. Promising and established treatment modalities include repair of the annulus fibrosis, injection of expanded or nonexpanded autologous or allogenic cells that are chondrogenic or from a stem cell lineage used to promote matrix tissue regeneration of the intervertebral disc, including nucleus pulpous cells and mesenchymal stem cells isolated from bone marrow, umbilical cord blood, or adipose tissue; and injection of platelet‐rich plasma, platelet‐rich fibrin, or fibrin sealant. Early clinical studies show promise for pain reduction and functional recovery. Level of Evidence Level V, expert opinion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, U.S.A.
- Laboratory for Regenerative Orthopaedics, Research Unit of Orthopaedic and Trauma Surgery, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy; Operative Research Unit of Orthopaedic an…
- Department of Orthopaedic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, U.S.A.. Electronic address: jdkang@bwh.harvard.edu.
Zitieren
APA
Mizuno, S., Vadala, G., & Kang, J. D. (2024). Biological Therapeutic Modalities for Intervertebral Disc Diseases: An Orthoregeneration Network (ON) Foundation Review. Arthroscopy, 40(3), 1019-1030. https://doi.org/10.1016/j.arthro.2023.10.032
Vancouver
Mizuno S, Vadala G, Kang JD. Biological Therapeutic Modalities for Intervertebral Disc Diseases: An Orthoregeneration Network (ON) Foundation Review. Arthroscopy. 2024;40(3):1019-1030. doi:10.1016/j.arthro.2023.10.032
BibTeX
@article{Mizuno2024,
author = {Mizuno, Shuichi and Vadala, Gianluca and Kang, James D},
title = {Biological Therapeutic Modalities for Intervertebral Disc Diseases: An Orthoregeneration Network (ON) Foundation Review},
journal = {Arthroscopy},
year = {2024},
volume = {40},
number = {3},
pages = {1019--1030},
doi = {10.1016/j.arthro.2023.10.032}
}
EUVIMED